Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6953858 | 0.99 | ITGB3 (0.59) | ITGB3ITGA2BF2F10PLAU | |
| SCHEMBL6949560 | 0.90 | ITGB3 (0.49) | ITGB3ITGA2B | |
| SCHEMBL6959161 | 0.90 | ITGB3 (0.49) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL6950979 | 0.89 | ITGB3 (0.59) | ITGB3ITGA2BF2F10PLAU | |
| SCHEMBL7034481 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2B | |
| SCHEMBL6954534 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2B | |
| SCHEMBL7028235 | 0.88 | ITGB3 (0.78) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL6950435 | 0.88 | ITGB3 (0.75) | ITGB3ITGA2BPLAU | |
| SCHEMBL6959422 | 0.87 | ITGB3 (0.47) | ITGB3ITGA2B | |
| SCHEMBL6955908 | 0.85 | ITGB3 (0.66) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014994-A1 | Method for resolving chiral (2s) and (2r) chromanes | ELI LILLY AND COMPANY | 2004-01-22 | — | — | US | disclosed |
| EP-1292588-A1 | METHODS FOR RESOLVING CHIRAL (2S) AND (2R) CHROMANES | Eli Lilly & Company (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094334-A1 | METHODS FOR RESOLVING CHIRAL (2S) AND (2R) CHROMANES | ELI LILLY & COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014994-A1 | Method for resolving chiral (2s) and (2r) chromanes | TBXA2R, TBXAS1, SRR | ITGB3 735/4885ITGA2B 2103/4885F2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.